{
  "source": "PA-Notification-Doptelet.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1250-8\nProgram Prior Authorization/Notification\nMedication Doptelet® (avatrombopag)\nP&T Approval Date 8/2018, 8/2019, 8/2020, 8/2021, 1/2022, 1/2023, 1/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nDoptelet (avatrombopag) is a thrombopoietin receptor agonist indicated for the treatment of\nthrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a\nprocedure. Doptelet is also indicated for the treatment of adult patients with chronic immune\nthrombocytopenia (ITP) who have had an insufficient response to a previous treatment.\n2. Coverage Criteriaa:\nA. Thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a\nprocedure\n1. Doptelet will be approved based on all of the following criteria:\na. Diagnosis of thrombocytopenia\n-AND-\nb. Patient has chronic liver disease\n-AND-\nc. Patient is scheduled to undergo a procedure\nAuthorization will be issued for 1 month.\nB. Chronic immune thrombocytopenia (ITP)\n1. Initial Authorization\na. Doptelet will be approved based on both of the following criteria\n(1) Diagnosis of chronic immune thrombocytopenia (ITP)\n-AND-\n(2) Patient has had an insufficient response to a previous treatment (e.g.,\ncorticosteroids, immunoglobulins, thrombopoietin receptor agonists, splenectomy)\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Doptelet will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Doptelet therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim",
    "d utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Doptelet [Package Insert]. Morrisville, NC: AkaRx, Inc.; July 2024.\nProgram Prior Authorization/Notification - Doptelet (avatrombopag)\nChange Control\n8/2018 New program.\n8/2019 Updated background and criteria with new indication in ITP. Updated\nreference.\n8/2020 Annual review with no changes to coverage criteria.\n8/2021 Annual review with no changes to coverage criteria. Updated reference.\n1/2022 Revised try/fail criteria to insufficient response. Updated reference.\n1/2023 Annual review with no changes to coverage criteria. Added state mandate.\n1/2024 Annual review with no changes to coverage criteria.\n1/2025 Annual review. Updated initial authorization for ITP to 12 months. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}